Corporate Governance - The board of directors consists of two executive directors and three independent non-executive directors, ensuring a diverse governance structure[3] Shareholder Information - BaWang International (Group) Holding Limited clarified the date for submitting share transfer documents for the annual general meeting is May 20, 2026, at 4:30 PM, not May 26, 2026, as previously stated[2]

Financial Performance - Total revenue for BaWang International (Group) Holding Limited reached approximately RMB 273.1 million, an increase of about 8.0% compared to RMB 253.0 million in the same period last year[2] - Operating profit decreased to approximately RMB 4.5 million, down about 41.2% from RMB 7.6 million in the previous year[2] - Net profit for the year was approximately RMB 3.9 million, a decline of about 40.7% compared to RMB 6.6 million in the same period last year[3] - Basic and diluted earnings per share were both RMB 0.1228, down from RMB 0.2073 in the previous year[4] - The company did not recommend the distribution of a final dividend based on the review of its operating performance[3] Revenue Breakdown - E-commerce channel revenue was approximately RMB 159.3 million, reflecting a growth of approximately 17.2% from RMB 135.9 million year-on-year[2] - The revenue for hair care products in 2025 was RMB 256,886 thousand, an increase from RMB 230,393 thousand in 2024, representing a growth of approximately 11.5%[14] - The total revenue for household and personal care products in 2025 was RMB 273,094 thousand, compared to RMB 252,952 thousand in 2024, indicating a growth of about 8%[14] - Revenue from external customers in China increased to RMB 269,996 thousand in 2025, up from RMB 250,143 thousand in 2024, representing a growth of approximately 7.4%[21] - Total revenue for the group reached RMB 273,094 thousand in 2025, compared to RMB 252,952 thousand in 2024, marking an increase of about 8%[21] Asset and Liability Management - Total assets minus current liabilities amounted to RMB 149.7 million, slightly down from RMB 151.1 million in the previous year[5] - Non-current assets increased to RMB 58.5 million from RMB 60.0 million year-on-year[5] - Cash and cash equivalents decreased to RMB 70.6 million from RMB 120.3 million in the previous year[5] - The company maintains a conservative financial management policy, with cash and bank balances of approximately RMB 115.6 million as of December 31, 2025, down from RMB 120.3 million in 2024[73] - Total assets as of December 31, 2025, are RMB 226.4 million, with a debt-to-asset ratio of 0%[74] Cost and Expenses - The cost of sales for 2025 is approximately RMB 134.2 million, an increase of about 8.1% from RMB 124.2 million in 2024, with the cost as a percentage of revenue slightly rising from 49.1% to 49.2%[46] - Gross profit increased to approximately RMB 138.8 million in 2025, up 7.8% from RMB 128.8 million in 2024, with a slight decrease in gross margin from 50.9% to 50.8%[47] - Selling and distribution expenses rose to approximately RMB 105.2 million, an increase of about 10.8% from RMB 94.9 million in 2024, with expenses as a percentage of revenue increasing from 37.5% to 38.5%[49][50] - Administrative expenses for 2025 are approximately RMB 32.1 million, up 9.4% from RMB 29.4 million in 2024, with expenses as a percentage of revenue increasing from 11.6% to 11.8%[51] Research and Development - Research and development costs recognized as expenses were RMB 14.1 million in 2025, up from RMB 13.0 million in 2024[26] - The company has established partnerships with several renowned universities and research institutions, enhancing its technical innovation capabilities and resulting in the publication of one journal article and the granting of one invention patent in the field of herbal medicine[67] - The R&D center spans 500 square meters and is equipped with advanced instruments such as HPLC and AAS, ensuring precise product testing and safety evaluations[68] Market Strategy and Brand Development - The company plans to enhance its brand products through continuous innovation in anti-hair loss technology, aiming to significantly improve market competitiveness[62] - The company intends to strengthen its brand positioning in professional hair care and expand its product offerings to attract younger consumers[63] - The company will optimize its product structure by phasing out underperforming product lines while promoting high-growth potential products[65] - The company has implemented a value chain-oriented business model to control sales and operating costs sustainably[34] - The company launched new product lines including Bawang toothpaste, Litao shower gel, and multi-effect nourishing series to meet diverse market demands[38] Operational Efficiency - The company has implemented automated production lines, optimizing internal management and production processes, which has effectively reduced costs and improved operational efficiency[69] - The company achieved zero industrial safety accidents throughout the year by enhancing safety training and emergency response capabilities for workers[70] Corporate Governance and Compliance - The company has complied with the corporate governance code as per the Hong Kong Stock Exchange rules as of December 31, 2025[82] - The audit and risk management committee has reviewed the group's annual performance for the year ended December 31, 2025, and recommended its adoption by the board[84] Future Outlook - The company plans to continue expanding its OEM business to enhance market share and influence in the industry[71] - Future strategies include forming management teams with rich experience in the household and personal care industry to restore sales growth and profitability[72] - The company will deepen insights into consumer demographics to drive product innovation and provide tailored solutions[66]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 BaWang International (Group) Holding Limited 霸王國際(集團)控股有限公司* 霸王國際(集團)控股有限公司(「本公司」)董事會(「董事會」)謹此公佈，本公司將 於二零二六年三月二十六日（星期四）舉行董事會會議，藉以(其中包括)考慮及批准 本公司及其附屬公司截至二零二五年十二月三十一日止年度之經審核業績，以及考慮 派發末期股息(如有)。 承董事會命 霸王國際（集團）控股有限公司* 陳啟源 主席 香港，二零二六年三月十一日 於本公告日期，本公司董事會由兩名執行董事陳啟源先生及陳正鶴先生，以及三名獨 立非執行董事張建榮先生、劉婧博士及朱達凱先生組成。 ( 於開曼群島註冊成立之有限公司 ) (股份代號: 01338) 董事會會議日期 * 僅供識別 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年2月28日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 霸王國際(集團)控股有限公司 呈交日期: 2026年3月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01338 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 10,000,000,000 | HKD | | 0.1 | HKD | | 1,000,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 10,000,000,000 | HKD | | 0.1 | HKD | | 1,000,000,000 | ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01338 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 10,000,000,000 | HKD | | 0.1 | HKD | | 1,000,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 10,000,000,000 | HKD | | 0.1 | HKD | | 1,000,000,000 | 本月底法定/註冊股本總額： HKD 1,000,000,000 第 1 頁 共 10 頁 v 1.2.0 截至月份: 2026年1月31日 狀態: 新提交 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性 亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而産生或因依賴該等內容而引致 的任何損失承擔任何責任。 BaWang International (Group) Holding Limited 霸王國際(集團)控股有限公司* （於開曼群島註冊成立之有限公司） 香港九龍尖沙咀柯士甸道 122 號麗斯中心 12 樓 B 室 承董事會命 霸王國際（集團）控股有限公司 陳啟源 主席 香港，二零二六年一月十五日 於本公佈日期，董事會由兩名執行董事陳啟源先生和陳正鶴先生，以及三名獨立非執 行董事張建榮先生、劉婧博士及朱達凱先生組成。 * 僅供識別 （股份代號 ：01338） 變更香港主要營業地點 霸王國際(集團)控股有限公司（「本公司」）董事會（「董事會」）謹此公佈，自二零二六 一月十五日起，本公司於香港之主要營業地點之地址將更改為: ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 霸王國際(集團)控股有限公司 呈交日期: 2026年1月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01338 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 10,000,000,000 | HKD | | 0.1 | HKD | | 1,000,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 10,000,000,000 | HKD | | 0.1 | HKD | | 1,000,000,000 | ...

(「本公司」) 定義 薪酬委員會的職權範圍 霸王國際（集團）控股有限公司 "股東" 指本公司的股東 "聯交所" 指香港聯合交易所有限公司 1. 就本職權範圍（「職權範圍 」）而言： "董事會" 指本公司的董事會 "企業管治守則" 指在上市規則附錄 C1 的《企業管治守則》 (不時修定) "公司秘書" 指本公司不時委任的公司秘書 "董事" 指本公司的董事 "财务总监" 指由董事會不時委任的負責公司財務管理的高級職員 "集團" 指本公司及其不時的附屬公司和關聯公司，或若文意另有 所指，於本公司成為其現時附屬公司和關聯公司的控股公 司前的有關期內，本公司現時的附屬公司和關聯公司，或 其現時附屬公司和關聯公司或其前身（視情況而定）所營 運的業務 "上市規則" 指聯交所不時修訂的上市規則 "薪酬" 指包括但不僅限於一切薪金、紅利、津貼、福利（現金或 實物）、 退休金安排、付還款項、補償款項（包括就任何 損失或終止聘用或委任而應付的補償）、獎勵金及購股權 "薪酬委員會" 指董事會根據本公司的組織章程第 117（1）條及本職權範 圍第 2 條通過的決議而不時設立的薪酬委員會 1 / 6 "高級管理人員" 指主席、首席執行官 ...

審核及風險管理委員會的職權範圍 霸王國際（集團）控股有限公司 (「本公司」) (股份代號：01338) 定義 1. 就本職權範圍（「職權範圍 」）而言： | "審核委員會" | 指董事會根據本公司的組織章程第 117（1）條及本 | | --- | --- | | | 職權範圍第 2 條通過的決議而不時設立的審核及風 | | | 險管理委員會 | "公司秘書" 指本公司不時委任的公司秘書 "聯交所" 指香港聯合交易所有限公司 組成 2. 董事會謹此議決在董事會下設立一個名為審核及風險管理委員會的董事會委員會。 成員 "董事" 指本公司的董事 "財務總監" 指由董事會委任的負責公司財務管理的高級職員 "集團" 指本公司及其不時的附屬公司和關聯公司 "上市規則" 指香港聯合交易所有限公司不時修訂的上市規則 "高級管理人員" 指主席、首席執行官、副首席執行官、首席財務 官、公司秘書及董事會不時委任的本公司其他管理 人員 3. 董事會將在本公司的非執行董事中不時委任審核委員會的成員, 審核委員會的成員數目將不少於三 名，大部份成員須為獨立非執行董事，而其中最少一位成員須為按上市規則的要求，具備適當專 業資格、或具備會 ...

提名委員會的職權範圍 定義 1. 對於引用（這些條款的目的條款）： | "董事會" | 指本公司董事會 | | --- | --- | | "企業管治守則" | 指在上市規則附錄C1的《企業管治守則》 (不時修定) | | "公司秘書" | 指本公司不時委任的公司秘書 | | "董事" | 指本公司的董事 | | "財務總監" | 指由董事會不時委任的負責公司財務管理的高級職員 | | "集團" | 指本公司及其不時的附屬公司和關聯公司，或若文意另 | | | 有所指，於本公司成為其現時附屬公司和關聯公司的控 | | | 股公司前的有關期內，本公司現時的附屬公司和關聯公 | | | 司，或其現時附屬公司和關聯公司或其前身（視情況而 | | | 定）所營運的業務 | 1 / 5 "上市規則" 指聯交所不時修訂的上市規則 "提名委員會" 指董事會根據本公司的組織章程第 117（1）條及本職權 範圍第 2 條通過的決議而設立的提名委員會 "高級管理人員" 指主席、首席執行官、副首席執行官、首席財務官、公 司秘書及董事會不時委任的本公司其他管理人員、本公 司任何其他管理人員(其薪酬福利條件比或將比董事會 委任的其他管 ...